Novel treatments for type 2 diabetes.
作者信息
Seewoodhary Jason, Bain Stephen C
出版信息
Br J Gen Pract. 2011 Jan;61(582):5-6. doi: 10.3399/bjgp11X548884.
Abstract
摘要
相似文献
1
Novel treatments for type 2 diabetes.
Br J Gen Pract. 2011 Jan;61(582):5-6. doi: 10.3399/bjgp11X548884.
2
Mental health providers' involvement in diabetes management.
Psychiatr Serv. 2007 Nov;58(11):1501-2. doi: 10.1176/ps.2007.58.11.1501.
3
DEVELOPMENT OF COMMUNITY HEALTH SERVICES: THE PHYSICIAN'S ROLE.
IMJ Ill Med J. 1965 Feb;127:163-7.
4
The physician's role in a community-based effort against the AIDS epidemic.
Cleve Clin J Med. 1987 Nov-Dec;54(6):473-4. doi: 10.3949/ccjm.54.6.473.
5
[A methodologic approach to the study of the physician's activities in health education].
Gig Sanit. 1988 Dec(12):38-40.
6
Diabetes care entering 2014: more ranting.
Diabetes Technol Ther. 2014 Feb;16(2):iii-iv. doi: 10.1089/dia.2014.0001.
7
Primary health care at the community level: the involvement of the doctor.
Trop Doct. 1981 Apr;11(2):92-3. doi: 10.1177/004947558101100216.
8
Community service by physicians.
J Fla Med Assoc. 1981 Jun;68(6):413.
9
Function of the community physician.
Br Med J. 1979 Jan 6;1(6155):58. doi: 10.1136/bmj.1.6155.58-b.
10
The physician as a community volunteer.
J Ark Med Soc. 1988 Nov;85(6):249-51.
引用本文的文献
1
Pyrazole Scaffold: Potential PTP1B Inhibitors for Diabetes Treatment.
Curr Diabetes Rev. 2024;21(2):e130224226925. doi: 10.2174/0115733998280245240130075909.
2
Novel treatments for type 2 diabetes.
Br J Gen Pract. 2011 May;61(586):325-6. doi: 10.3399/bjgp11X572355.
本文引用的文献
1
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review.
Diabetes Metab Syndr Obes. 2010 May 17;3:155-63.
2
SGLT2 inhibition--a novel strategy for diabetes treatment.
Nat Rev Drug Discov. 2010 Jul;9(7):551-9. doi: 10.1038/nrd3180. Epub 2010 May 28.
3
Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.
Diabetes Care. 2010 Jul;33(7):1503-8. doi: 10.2337/dc09-2009. Epub 2010 Mar 23.
4
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
Lancet. 2009 Jul 11;374(9684):126-35. doi: 10.1016/S0140-6736(09)60870-9. Epub 2009 Jun 8.
5
Exenatide-associated ischemic renal failure.
Diabetes Care. 2009 Feb;32(2):e22-3. doi: 10.2337/dc08-1309.
6
Exenatide and pancreatitis: an update.
Expert Opin Drug Saf. 2008 Nov;7(6):643-4. doi: 10.1517/14740330802432003.
7
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.
Rev Diabet Stud. 2008 Summer;5(2):73-94. doi: 10.1900/RDS.2008.5.73. Epub 2008 Aug 10.
8
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845.
9
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
Curr Med Res Opin. 2008 Jan;24(1):275-86. doi: 10.1185/030079908x253870.
10
Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats.
Diabetes. 2006 Jun;55(6):1747-54. doi: 10.2337/db05-1443.
Zotero 插件